SENTI BIOSCIENCES INC
Senti Biosciences (SNTI) is a synthetic biology company developing programmable cell therapies and biologics. Using a proprietary genetic-circuit platform, the company aims to design cells that respond selectively in the body, with potential applications in oncology and inflammatory disease. The business is early‑stage and largely preclinical; progress depends on R&D milestones, partnerships and future financing. With a market capitalisation of about $53.6m, Senti is a small-cap biotech and can be volatile — clinical setbacks, regulatory hurdles and funding needs may materially affect the share price. Investors should monitor pipeline updates, cash runway, partner deals and regulatory progress. This summary is for general educational purposes only and does not constitute personalised investment advice. Biotech investments carry high risk and it is sensible to consider diversification and whether this fits your risk tolerance before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Senti Biosciences' stock, expecting its price to rise significantly.
Financial Health
Senti Biosciences is showing solid financial results with strong cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SNTI
Cancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: June 17, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage biotech growth
Pipeline progress and clinical milestones can move the stock, though outcomes are uncertain and future capital raises may dilute shareholders.
Platform innovation focus
Programmable genetic circuits aim to improve therapeutic precision, but technological and regulatory hurdles mean success is not guaranteed.
Partnerships and funding
Collaborations and financing often drive development pace; watch cash runway and deal announcements as key signals of momentum.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
